Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | MTOR | P42345 | 1/20 | 0.59 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.59 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.50 |
| ▸ | ST6GAL1 | P15907 | 8/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585577 | 0.88 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL11858047 | 0.87 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL4586059 | 0.86 | LMNA (0.58) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13678671 | 0.84 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL441997 | 0.84 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL236108 | 0.84 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL6060610 | 0.84 | LMNA (0.69) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL338768 | 0.83 | POLB (0.56) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL11852550 | 0.83 | LMNA (0.65) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL9667473 | 0.83 | LMNA (0.65) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097711-B2 | nucleoside monomers protected with thioether substituted aryl carbonate protecting groups; oligonucleotides, using such protected nucleoside monomer monomers, as well as nucleic acids | AGILENT TECHNOLOGIES, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20080146787-A1 | Thioether substituted aryl carbonate protecting groups | AGILENT TECHNOLOGIES, INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146787-A1 | Thioether substituted aryl carbonate protecting groups | NSUN2, NSUN3, TRDMT1 | LMNA 426/4885THRB 2353/4885MTOR 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.